The COVID-19 pandemic: key considerations for the epidemic and its control
- PMID: 33932317
- PMCID: PMC8239778
- DOI: 10.1111/apm.13141
The COVID-19 pandemic: key considerations for the epidemic and its control
Abstract
The response to the ongoing COVID-19 pandemic has been characterized by draconian measures and far too many important unknowns, such as the true mortality risk, the role of children as transmitters and the development and duration of immunity in the population. More than a year into the pandemic much has been learned and insights into this novel type of pandemic and options for control are shaping up. Using a historical lens, we review what we know and still do not know about the ongoing COVID-19 pandemic. A pandemic caused by a member of the coronavirus family is a new situation following more than a century of influenza A pandemics. However, recent pandemic threats such as outbreaks of the related and novel deadly coronavirus SARS in 2003 and of MERS since 2012 had put coronaviruses on WHOs blueprint list of priority diseases. Like pandemic influenza, SARS-CoV-2 is highly transmissible (R0 ~ 2.5). Furthermore, it can fly under the radar due to a broad clinical spectrum where asymptomatic and pre-symptomatic infected persons also transmit the virus-including children. COVID-19 is far more deadly than seasonal influenza; initial data from China suggested a case fatality rate of 2.3%-which would have been on par with the deadly 1918 Spanish influenza. But, while the Spanish influenza killed young, otherwise healthy adults, it is the elderly who are at extreme risk of dying of COVID-19. We review available seroepidemiological evidence of infection rates and compute infection fatality rates (IFR) for Denmark (0.5%), Spain (0.85%), and Iceland (0.3%). We also deduce that population age structure is key. SARS-CoV-2 is characterized by superspreading, so that ~10% of infected individuals yield 80% of new infections. This phenomenon turns out to be an Achilles heel of the virus that may explain our ability to effectively mitigate outbreaks so far. How will this pandemic come to an end? Herd immunity has not been achieved in Europe due to intense mitigation by non-pharmaceutical interventions; for example, only ~8% of Danes were infected across the 1st and 2nd wave. Luckily, we now have several safe and effective vaccines. Global vaccine control of the pandemic depends in great measure on our ability to keep up with current and future immune escape variants of the virus. We should thus be prepared for a race between vaccine updates and mutations of the virus. A permanent reopening of society highly depends on winning that race.
Keywords: COVID-19; Coronavirus; mortality; pandemic; superspreading.
© 2021 APMIS. Published by John Wiley & Sons Ltd.
Figures



Similar articles
-
Insights into COVID-19 Vaccine Development Based on Immunogenic Structural Proteins of SARS-CoV-2, Host Immune Responses, and Herd Immunity.Cells. 2021 Oct 29;10(11):2949. doi: 10.3390/cells10112949. Cells. 2021. PMID: 34831172 Free PMC article. Review.
-
[Technical guidelines for seasonal influenza vaccination in China (2021-2022)].Zhonghua Liu Xing Bing Xue Za Zhi. 2021 Oct 10;42(10):1722-1749. doi: 10.3760/cma.j.cn112338-20210913-00732. Zhonghua Liu Xing Bing Xue Za Zhi. 2021. PMID: 34814607 Chinese.
-
Human and novel coronavirus infections in children: a review.Paediatr Int Child Health. 2021 Feb;41(1):36-55. doi: 10.1080/20469047.2020.1781356. Epub 2020 Jun 25. Paediatr Int Child Health. 2021. PMID: 32584199 Review.
-
[Technical guidelines for seasonal influenza vaccination in China (2020-2021)].Zhonghua Yu Fang Yi Xue Za Zhi. 2020 Oct 6;54(10):1035-1059. doi: 10.3760/cma.j.cn112150-20200911-01198. Zhonghua Yu Fang Yi Xue Za Zhi. 2020. PMID: 33131228 Chinese.
-
The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem.J Biol Regul Homeost Agents. 2021 Jan-Feb;35(1):1-4. doi: 10.23812/21-3-E. J Biol Regul Homeost Agents. 2021. PMID: 33377359
Cited by
-
Severe COVID-19 Shares a Common Neutrophil Activation Signature with Other Acute Inflammatory States.Cells. 2022 Mar 1;11(5):847. doi: 10.3390/cells11050847. Cells. 2022. PMID: 35269470 Free PMC article.
-
Market potentials of robotic systems in medical science: analysis of the Avatera robotic system.World J Urol. 2022 Jan;40(1):283-289. doi: 10.1007/s00345-021-03809-z. Epub 2021 Aug 23. World J Urol. 2022. PMID: 34424374 Free PMC article.
-
Next-generation vaccines for influenza B virus: advancements and challenges.Arch Virol. 2025 Jan 6;170(2):25. doi: 10.1007/s00705-024-06210-4. Arch Virol. 2025. PMID: 39762648 Review.
-
Heterogeneity in testing for infectious diseases.R Soc Open Sci. 2022 May 18;9(5):220129. doi: 10.1098/rsos.220129. eCollection 2022 May. R Soc Open Sci. 2022. PMID: 35600424 Free PMC article.
-
Trust in the U.S. Government and Its Health Agencies in the Time of COVID-19.Epidemiologia (Basel). 2022 Mar 22;3(2):148-160. doi: 10.3390/epidemiologia3020012. Epidemiologia (Basel). 2022. PMID: 36417248 Free PMC article.
References
-
- Miller MA, Viboud C, Balinska M, Simonsen L. The signature features of influenza pandemics — implications for policy. N Engl J Med. 2009;360:2595–8. - PubMed
-
- Simonsen L, Clarke MJ, Schonberger LB, Arden NH, Cox NJ, Fukuda K, et al. Pandemic versus epidemic influenza mortality: a pattern of changing age distribution. J Infect Dis. 1998;178:53–60. - PubMed
-
- Murray CJL, Lopez AD, Chin B, Feehan D, Hill KH. Estimation of potential global pandemic influenza mortality on the basis of vital registry data from the 1918–20 pandemic: a quantitative analysis. The Lancet. 2006;368:2211–18. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous